Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,501.24
(
0.77%
)
US TECH 100
28,788.80
(
0.70%
)
Dow Jones
50,063.46
(
0.75%
)
Brent Oil
104.89
(
0.68%
)
Bitcoin
80,413.44
(
-0.79%
)
News Focus
News Focus
Post# of 257566
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122982
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: rwdm post# 143422

Friday, 05/09/2014 4:04:45 PM

Friday, May 09, 2014 4:04:45 PM

Post# of 257566
Is Merck KGaA FoB partnership with RDY inked in 2012 (#msg-76359649) defunct? This piece from FiercePharma mentions it not at all:

http://www.fiercepharma.com/story/merck-kgaa-pour-138m-biosimilars-licensing-instead-ma/2014-05-09

Merck KGaA has plenty of resources to devote to big M&A deals… But company executives told shareholders at its annual meeting on Friday that future growth may be less about giant acquisitions than it is about making strategic deals and internal changes to boost its pipeline.

Toward that end, the company is searching for pharma licensing deals and planning to invest €100 million ($138 million) in biosimilars, according to a company statement.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today